Topic summary

Prescription requirements and telehealth models — a second dataset

Sourcing › Regulatory compounding EMA MHRA personal import FDA

This is a generated summary. It shows the 9 most-liked posts from a topic of 95, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

a.pereiraTL214 Apr 2026#3

micrograms, post #1: On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. Posting a small dataset on Prescription requirements and telehealth models. It is mine, it is uncontrolled, and the method is stated so it can be discounted appropriately. What I would like is not… Go to post

Adding the measurement that post #2 says would settle it.

Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.

24 likes in reply to #1 3mo

j.mwangiTL4 Moderator23 Apr 2026#10

Coming back to post #8, because the follow-up matters more than the original answer.

Prescription requirements and telehealth models came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.

23 likes 3mo

GEldridgeTL3Regular2 May 2026#17

d.eriksen, post #7: Adding a note of thanks rather than an opinion. I did not know most of that. Go to post

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

I have said this before in a thread nobody could find, so it is worth repeating.

28 likes in reply to #7 3mo

i.dumitruTL28 May 2026#23

s.kimani, post #9: Post #6 is right about the mechanism and I think understates the practical bit. An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence. This has been discussed before and I could not find the thread, so, again. Go to post

Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.

23 likes in reply to #9 3mo

l.parkinsonTL2Member13 May 2026#28

That reframing is the whole thing. The facts I already had.

32 likes 3mo

cohort_driftTL3Regular20 May 2026#36

s.ivaturi, post #25: Worth separating Prescription requirements and telehealth models as a question about the compound from Prescription requirements and telehealth models as a question about the documentation. They get answered by different people and only one of them is answerable here. Go to post

This follows post #33 rather than contradicting it.

A definition problem is doing most of the work in this Prescription requirements and telehealth models discussion. Once the term is pinned down I suspect the disagreement mostly goes away and what is left is small.

30 likes in reply to #25 2mo

owen.bradyTL4 Moderator13 Jun 2026#64

Post #62 put the caveat in the right place and I want to underline it.

Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.

If anyone has run this properly I would rather read that than my own guess.

25 likes 1mo

n.silvaTL220 Jun 2026#72

Picking up post #69: that is the part I would want checked first.

The useful distinction on Prescription requirements and telehealth models is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error bars.

23 likes 1mo

s.grimaldiTL223 Jun 2026#76

On Prescription requirements and telehealth models, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.

If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.

31 likes 1mo

Read the full topic (95 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
Pharmaceutical compounding rules, summarised from primary sources Sourcing › Regulatory MHRA EMA research use only Closed Pharmaceutical compounding rules, summarised from primary sources — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since the summaries of…	+135	163	46k	17mo
Coming back to: Research-use-only labelling: what it means and what it does not Sourcing › Regulatory MHRA personal import research use only Solved Research-use-only labelling: what it means and what it does not — setting out what I have, and where I think it stops being reliable. A labelling question, and I would like the answer to be about what the…	+45	50	39k	20mo
What a regulator's shortage notice actually authorises — what changed since Sourcing › Regulatory research use only EMA FDA compounding Solved The question in the title: What a regulator's shortage notice actually authorises — what changed since I will give what I have already checked below so nobody repeats it. Asking what a regulator's document…	+22	26	53k	7mo
Why a compound being unapproved is not the same as being illegal to possess Sourcing › Regulatory FDA MHRA research use only EMA Why a compound being unapproved is not the same as being illegal to possess I have a specific reason for asking rather than idle curiosity, and the context is below. Collecting what is known about compound…	+72	78	23k	3mo
How compounding permissions changed when supply normalised Sourcing › Regulatory personal import EMA compounding research use only Solved Asking directly, because I could not find a straight answer: How compounding permissions changed when supply normalised I was wrong about compounding permissions in a thread last spring and I would like to…	+30	34	51k	16mo

Related topics — sharing the tags compounding, EMA, MHRA

Topic	Participants	Replies	Views	Activity
Hoarding and why it makes a shortage worse Access › Shortages formulary shortage compounding FDA Posting this under the heading it deserves: Hoarding and why it makes a shortage worse Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this category…		2	12k	22mo
Why this community will not facilitate a group purchase Sourcing › Payments documentation quality payments research use only Asking directly, because I could not find a straight answer: Why this community will not facilitate a group purchase Currency and fees, set out so that the comparison can be checked. Quoted amount, conversion…		2	40k	3mo
Language barriers in accessing a prescription abroad Access › International personal import telehealth EMA Solved Language barriers in accessing a prescription abroad Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about language barriers in accessing in a thread last spring…		2	22k	1h
Coming back to: Private prescribing in the UK: what is actually involved Regional › UK & Ireland personal import MHRA NHS cost per milligram Private prescribing in the UK: what is actually involved Writing it up because I had to work it out twice and would rather nobody else did. I would like to know what people here actually do about Private…	+62	67	2.1k	6mo
What changed in 2026, by region Access › International EMA NHS personal import Solved What changed in 2026, by region — that is the question, and I have not found it answered plainly anywhere I have looked. Documenting an access outcome, dated, because everything in this category expires. As…	+110	122	1.4k	18mo